Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Mar 17, 2021

by Zacks Equity Research

Companies in the news are: JBL, CNF, OPRX, MRNA

Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal

by Zacks Equity Research

Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.

AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots

by Zacks Equity Research

The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

by Zacks Equity Research

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

J&J (JNJ) Outperforms the Industry Year to Date: Here's Why

by Zacks Equity Research

J&J's (JNJ) shares are up this year mainly due to successful development of its COVID-19 vaccine.

Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.

Sweta Killa headshot

Air Travel Demand Nears 1-Year High: ETFs to Fly High

by Sweta Killa

According to the latest data from Transportation Security Administration (TSA), about 1.357 million travelers checked in at American airports on Mar 12 - the highest number since Mar 15, 2020.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

by Zacks Equity Research

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.

AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data

by Zacks Equity Research

AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.

Stock Market News for Mar 12, 2021

by Zacks Equity Research

Benchmarks closed in the positive territory on Thursday after President Biden signed a $1.9 trillion stimulus package to boost the coronavirus pandemic plagued economy, while tech shares also made a comeback

J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe

by Zacks Equity Research

J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

by Zacks Equity Research

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

Mark Vickery headshot

Dow Hits New All-Time High Close as Rescue Bill Passes

by Mark Vickery

Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study

by Zacks Equity Research

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Sweta Killa headshot

5 Beaten-Down Stocks of Nasdaq ETF With Upside Potential

by Sweta Killa

We highlighted five stocks from the ETF that were hit badly in the tech rout but might reverse the trend, given their solid Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive earnings estimate revisions in a month.

Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains

by Zacks Equity Research

Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.

Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II

by Zacks Equity Research

Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.

IBM & Moderna Partner to Augment COVID-19 Vaccine Management

by Zacks Equity Research

IBM and Moderna (MRNA) team up to explore utility of hybrid cloud and blockchain technology to enhance COVID-19 vaccine management and stem the spread of the contagion.

Kevin Cook headshot

Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

by Kevin Cook

New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Rimmi Singhi headshot

5 High Earnings Yield Picks That Command Your Attention

by Rimmi Singhi

Level up your portfolio with high earnings yield stocks including ArcelorMittal (MT), Moderna, (MRNA), Shell (RDS.A), Magna (MGA), Winnebago (WGO).

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

by Zacks Equity Research

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.